AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

President Donald Trump has withdrawn his nomination of Dave Weldon to lead the CDC, just hours before he was due to appear in ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) had been scheduled to meet to discuss the strains that should be included in the seasonal vaccine yesterday but was abruptly ...

Abzena, a San Diego-based CDMO and CRO focused on bioconjugates and complex biologics, has welcomed Taylor Boyd as its new ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...